Platforms for synthesis and testing of emerging and zoonotic viruses
新兴病毒和人畜共患病毒的合成和测试平台
基本信息
- 批准号:8234184
- 负责人:
- 金额:$ 52.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAttenuatedBioinformaticsBiological ModelsBioterrorismCategoriesChiropteraClinicalComputer SimulationCoronavirusCultured CellsDatabasesDeletion MutationDevelopmentDistantEngineeringEpidemicEpithelial CellsFerretsFrequenciesFutureGenetic TranscriptionGenomeGoalsGrowthHumanHuman VirusIn VitroInterferonsInterventionKineticsMapsMissionModelingMolecular BiologyMovementMusMutationOrganismPathogenesisPharmaceutical PreparationsPhenotypePhylogenetic AnalysisPolyproteinsProteinsPublic HealthRecombinantsRecoveryRoleSARS coronavirusSourceSubgroupSystemTestingTransgenic MiceVaccinesVariantViralVirulenceVirusVirus ReceptorsViverridaeagedattenuationbiodefensecoronavirus spike glycoproteindesignengineering designhuman coronavirushuman diseasein vivomouse modelnovel viruspandemic diseasepathogenpreventprogramsreceptorrecombinational repairreconstructionreplicaseresponsesenescencestructural biologysynthetic biologytooltransmission process
项目摘要
There has been an increase in recognized trans-species movement and human disease from zoonotic
viruses, as well as increased concern about intentional design and introduction of zoonotic organisms in
bioterrorism. Our ability to respond to such emerging zoonotic-human viruses has been limited by our
inability to predict the source, frequency, and mechanisms of virus host-species switching and adaptation.
Recent advances in bioinformatics, molecular biology, structural biology, and synthetic biology, provide tools
to design, synthetically reconstruct, and test new and emerging pathogens from sequence databases alone.
However, development of broadly-applicable platforms strategies for emerging viruses has not occurred, in
part due to concerns about possible misuse of synthetic biology and engineered host-range variants. We
propose that is an essential mission of the RCEs to demonstrate the safe use and potential of synthetic
biology in rapid response platforms. SARS-coronavirus (SARS-CoV) is a category C emerging pathogen that
caused severe human disease worldwide. SARS-CoV is proposed to have emerged in humans following
trans-species movement of Bat-Coronaviruses (Bat-CoV) that have been identified by sequence but have
not been grown in culture. This proposal uses SARS-CoV and zoonotic Bat-CoV to establish platforms for
recovery and testing of zoonotic viruses. The proposed program is comprised of four integrated Specific
Aims that will design and synthetically reconstruct distinct serogroups of zoonotic bat-CoV from sequence
databases, and define the determinants of host-species movement and adaptation in culture, and in young
and senescent mouse models. Further, the Aims will develop strategies for stable and universal attenuation
of pathogenesis of all coronavirus groups. The established approaches will allow rapid response and control
of natural and deliberately designed human coronaviruses, and also will be directly applicable to
development of similar specific rapid-response systems for recovery, analysis, attenuation and response to
other category A, B, or C emerging pathogens of concern for human disease or bioterrorism.
公认的跨物种移动和人畜共患病的人类疾病有所增加
病毒,以及对故意设计和引入人畜共患生物体的日益关注
生物恐怖主义。我们应对此类新出现的人畜共患病毒的能力受到我们的限制。
无法预测病毒宿主物种转换和适应的来源、频率和机制。
生物信息学、分子生物学、结构生物学和合成生物学的最新进展提供了工具
仅从序列数据库中设计、综合重建和测试新的和正在出现的病原体。
然而,针对新兴病毒的广泛适用的平台策略尚未开发出来。
部分原因是担心合成生物学和工程宿主范围变异可能被滥用。我们
提出 RCE 的一项基本任务是展示合成药物的安全使用和潜力
快速反应平台中的生物学。 SARS 冠状病毒 (SARS-CoV) 是一种 C 类新发病原体,
在全世界范围内引起了严重的人类疾病。 SARS-CoV 被认为是在人类中出现的
蝙蝠冠状病毒(Bat-CoV)的跨物种移动已通过序列鉴定,但
没有在文化中成长。该提案利用 SARS-CoV 和人畜共患蝙蝠-CoV 建立平台
人畜共患病病毒的回收和测试。拟议的计划由四个综合具体
目标是根据序列设计和综合重建人畜共患蝙蝠冠状病毒的不同血清群
数据库,并定义文化和年轻人中宿主物种运动和适应的决定因素
和衰老小鼠模型。此外,目标将制定稳定和普遍衰减的策略
所有冠状病毒群的发病机制。既定方法将允许快速响应和控制
天然和精心设计的人类冠状病毒,也将直接适用于
开发类似的特定快速响应系统,用于恢复、分析、衰减和响应
其他 A、B 或 C 类新出现的引起人类疾病或生物恐怖主义的病原体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark R Denison其他文献
Mark R Denison的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark R Denison', 18)}}的其他基金
Inhibitors of Coronavirus Fidelity and Cap Methylation as Broadly Applicable
冠状病毒保真度和帽甲基化抑制剂广泛适用
- 批准号:
9217551 - 财政年份:2014
- 资助金额:
$ 52.09万 - 项目类别:
Platforms for synthesis and testing of emerging and zoonotic viruses
新兴病毒和人畜共患病毒的合成和测试平台
- 批准号:
8375872 - 财政年份:2012
- 资助金额:
$ 52.09万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 52.09万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 52.09万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 52.09万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 52.09万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 52.09万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 52.09万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 52.09万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 52.09万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 52.09万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 52.09万 - 项目类别:
Idea to Innovation














{{item.name}}会员




